Itraconazole increases plasma concentrations of quinidine

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 5, 1997, Pages 510-517

  Kaukonen, Kirsi Maija ^a   Olkkola, Klaus T ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; HYDROXYITRACONAZOLE; ITRACONAZOLE; QUINIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG URINE LEVEL; ELECTROCARDIOGRAM; FEMALE; FLUORESCENCE; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL;

ADMINISTRATION, ORAL; ADULT; ANTI-ARRHYTHMIA AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; ITRACONAZOLE; MALE; MIXED FUNCTION OXYGENASES; QUINIDINE; REFERENCE VALUES; TIME FACTORS;

EID: 0031412569     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90046-1     Document Type: Article

References (30)

1. Cohen IS, Jick H, Cohen SI. Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program. Prog Cardiovasc Dis 1977;20:151-63.
2. Inaba T, Tyndale RE, Mahon WA. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo [letter]. Br J Clin Pharmacol 1986;22:199-200.
3. Nielsen F, Rosholm JU, Brøsen K. Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism. Eur J Clin Pharmacol 1995;48:501-4.
4. Guengerich FP, Müller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986;30:287-95.
5. Dollery C, editor. Therapeutic drugs; vol 2. Edinburgh: Churchill Livingstone; 1991. p. Q4-8.
6. Hardy BG, Zador IT, Golden L, Lalka D, Schentag JJ. Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. Am J Cardiol 1983; 52:172-5.
7. Hardy BG, Schentag JJ. Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. Int J Clin Pharmacol Ther Toxicol 1988;26:388-91.
8. Laganière S, Davies RF, Carignan G, Foris K, Goernert L, Carrier K, et al. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. Clin Pharmacol Ther 1996;60:255-64.
9. Matera MG, De Santis D, Vacca C, Fici F, Romano AR, Marrazzo R, et al. Quinidine-diltiazem: pharmacokinetic interaction in humans. Curr Ther Res 1986; 40:653-6.
10. Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994;37:221-5.
11. Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 1996;59:369-75.
12. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
13. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-7.
14. Edstein MD, Prasitthipayong A, Sabchareon A, Chongsuphajaisiddhi T, Webster HK. Simultaneous measurement of quinine and quinidine in human plasma, whole blood and erythrocytes by high-performance liquid chromatography. Ther Drug Monit 1990;12:493-500.
15. Thompson KA, Murray JJ, Blair IA, Woosley RL, Roden DM. Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades des pointes. Clin Pharmacol Ther 1988; 43:636-42.
16. Drayer DE, Lowenthal DT, Restivo KM, Schwartz A, Cook CE, Reidenberg MM. Steady-state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function. Clin Pharmacol Ther 1978;24:31-9.
17. Allenmark S, Edebo A, Lindgren K. Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence detection. J Chromatogr 1990;532:203-6.
18. Bazett HC. An analysis of the time relations of electrocardiograms. Heart 1920;7:353-70.
19. Ochs HR, Greenblatt DJ, Woo E. Clinical pharmacokinetics of quinidine. Clin Pharmacokinet 1980;5: 150-68.
20. Raunio H, Pasanen M, Mäenpää J, Hakkola J, Pelkonen O. Expression of extrahepatic cytochrome P450 in humans. In: Pacifici GM, Fracchia GN, editors. Advances in drug metabolism in man. Luxembourg: Office for official publications of the European Communities; 1995. p. 233-87.
21. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997;61:410-5.
22. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61.
23. Notterman DA, Drayer DE, Metakis L, Reidenberg MM. Stereoselective renal tubular secretion of quinidine and quinine. Clin Pharmacol Ther 1986;40: 511-7.
24. de Lannoy IAM, Silverman M. The mdr-1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992;189:551-7.
25. Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997 [in press].
26. de Lannoy IAM, Koren G, Klein J, Charuk J, Silverman M. Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. Am J Physiol 1992;263:F613-22.
27. Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993;21:403-9.
28. Crevasse L. Quinidine: an update on therapeutics, pharmacokinetics and serum concentration monitoring. Am J Cardiol 1988;62:22I-23I.
29. McNulty RM, Lazor JA, Sketch M. Transient increase in plasma quinidine concentrations during ketoconazole-quinidine therapy. Clin Pharmacokinet 1989;8:222-5.
30. Spinier SA, Cheng JWM, Kindwall KE, Charland SL. Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther 1995;57:89-94.